Neutralizing Antibodies to Interferon-β in Multiple Sclerosis

Interferon-β is an established and important immunomodulatory drug employed in the treatment of multiple sclerosis (MS).  A significant proportion (~30%) of patients receiving interferon-β treatments develop drug-induced antibodies, which bind to the drug but do not necessarily block biological activity.  However, a large proportion of this subgroup of patients (~80%) come to produce neutralizing antibodies (NAbs), which do reduce drug efficacy when present at high levels.

Anti-IFN-β NAb Testing by Cell-Based Assay (CBA)

Patient sera are screened for NAb positivity via a cell line transfected with the IFI-161 promoter linked to a luciferase reporter.  If NAbs are not present, the luciferase substrate will illuminate.  A positive result of NAb presence yields reduced illumination, which can be quantified in Tenfold Reduction Units (TRU)/mL and categorized into tiers of low, medium, and high antibody titres.  Persistently high Ab titres signify poor therapeutic efficacy, and indicate the need for an alternate therapeutic strategy.

Laboratory Requisition

EN / FR
*Download the requisition onto a computer and open with Adobe Acrobat/Reader for a writeable PDF